1,3,5-Triazine and azole can interact with various therapeutic targets, and their derivatives possess promising in vitro and in vivo anticancer activity. Hybrid molecules have the potential to enhance efficiency, overcome drug resistance and reduce side effects, and many hybrid molecules are under different phases of clinical trials, so hybridization of 1,3,5-triazine with azole may provide valuable therapeutic intervention for the treatment of cancer. Substantial efforts have been made to develop azole-containing 1,3,5-triazine hybrids as novel anticancer agents, and some of them exhibited excellent activity. This review emphasizes azole-containing 1,3,5-triazine hybrids with potential anticancer activity, and the structure-activity relationships as well as the mechanisms of action are also discussed to provide comprehensive and target-oriented information for the development of this kind of anticancer drugs.

1,3,5-三嗪和唑可以与各种治疗靶点相互作用，它们的衍生物具有有希望的体外和体内抗癌活性。杂合分子具有提高效率，克服耐药性和减少副作用的潜力，并且许多杂合分子处于临床试验的不同阶段，因此1,3,5-三嗪与唑的杂合可能为治疗甲氧西林提供有价值的治疗干预措施。癌症。为了开发作为新型抗癌剂的含唑的1,3,5-三嗪杂种，已经做出了巨大的努力，其中一些具有优异的活性。这篇评论重点介绍了具有潜在抗癌活性的含唑1,3,5-三嗪杂种，